56 related articles for article (PubMed ID: 8084436)
1. [Experience regarding the use of arginine-lysine-lactose treatment in menopausal osteoporosis].
Bellati U; Liberati M
Minerva Med; 1994 Jun; 85(6):327-32. PubMed ID: 8084436
[TBL] [Abstract][Full Text] [Related]
2. [The effects of the carbocalcitonin + arginine-lysine-lactose combination in senile involutional osteoporosis].
Abate G; Taormina F; Brillante C; Fraccalaglio L
Minerva Med; 1994 May; 85(5):253-9. PubMed ID: 8028755
[TBL] [Abstract][Full Text] [Related]
3. [Experimental osteoporosis caused by estrogen deficiency in rats. Role of a lactose, L-arginine and L-lysine combination in the prevention and therapy].
Fini M; Giardino R; Mongiorgi R; Cantelli Forti G; Gnudi S; Nicoli Aldini N; Valdrè C; Piotti D; Giavaresi G; Orienti L; Rocca M; Sapone A; Rossetti A
Minerva Med; 1996 Mar; 87(3):81-8. PubMed ID: 8668292
[TBL] [Abstract][Full Text] [Related]
4. Calcitriol and alendronate combination treatment in menopausal women with low bone mass.
Malavolta N; Zanardi M; Veronesi M; Ripamonti C; Gnudi S
Int J Tissue React; 1999; 21(2):51-9. PubMed ID: 10568224
[TBL] [Abstract][Full Text] [Related]
5. [Role of lactose, arginine and lysine combination in fracture healing (an experimental study)].
Fini M; Giardino R; Nicoli Aldini N; Martini L; Rocca M; Bertoni F; Capelli S; Cantelli Forti G; Sapone A; Rossetti A; Morrone G; Giavaresi G
Ann Ital Chir; 1996; 67(1):77-82; discussion 82-3. PubMed ID: 8712622
[TBL] [Abstract][Full Text] [Related]
6. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
7. Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis.
Gur A; Colpan L; Cevik R; Nas K; Jale Sarac A
Clin Biochem; 2005 Jan; 38(1):66-72. PubMed ID: 15607319
[TBL] [Abstract][Full Text] [Related]
8. [Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate].
Buffo L; Rossini M; Buoncristiano A; Girardello S; Zamberlan N; Diani F; Adami S
Minerva Ginecol; 1996 Jun; 48(6):263-72. PubMed ID: 8927288
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
Stĕpán J; Formánková J; Masatová A; Michalský M; Rosenová Z
Cas Lek Cesk; 1997 Apr; 136(8):242-8. PubMed ID: 9264868
[TBL] [Abstract][Full Text] [Related]
10. The effect of calcitonin treatment on plasma nitric oxide levels in post-menopausal osteoporotic patients.
Taş N; Aricioglu A; Erbas D; Ozcan S
Cell Biochem Funct; 2002 Jun; 20(2):103-5. PubMed ID: 11979505
[TBL] [Abstract][Full Text] [Related]
11. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
12. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
[TBL] [Abstract][Full Text] [Related]
13. Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women.
Yasui T; Miyatani Y; Tomita J; Yamada M; Uemura H; Miura M; Irahara M
Gynecol Endocrinol; 2006 Aug; 22(8):455-9. PubMed ID: 17012108
[TBL] [Abstract][Full Text] [Related]
14. [Observations on bone mineral metabolism in natural and surgical menopause. Role of synthetic salmon calcitonin and calcium on bone turnover].
Ferrante B; Isa L; Uderzo A
Minerva Ginecol; 1993 Mar; 45(3):87-93. PubMed ID: 8332282
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
16. L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history.
La Vignera S; Vicari E; Tumino S; Ciotta L; Condorelli R; Vicari LO; Calogero AE
Minerva Ginecol; 2008 Dec; 60(6):475-84. PubMed ID: 18981975
[TBL] [Abstract][Full Text] [Related]
17. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
Bunyavejchevin S; Limpaphayom KK
J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
[TBL] [Abstract][Full Text] [Related]
18. [Effects of warm needle moxibustion on bone mass density and biochemical indexes of bone metabolism in patients of postmenopausal osteoporosis].
Zhao LH; Nong ZN; Zhong X; Pang Y; Liang JS; Li XD; Ye FW
Zhongguo Zhen Jiu; 2008 Dec; 28(12):897-900. PubMed ID: 19127918
[TBL] [Abstract][Full Text] [Related]
19. Genetically defined adult-type hypolactasia and self-reported lactose intolerance as risk factors of osteoporosis in Finnish postmenopausal women.
Enattah N; Pekkarinen T; Välimäki MJ; Löyttyniemi E; Järvelä I
Eur J Clin Nutr; 2005 Oct; 59(10):1105-11. PubMed ID: 16015262
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
Cecchettin M; Bellometti S; Cremonesi G; Solimeno LP; Torri G
Biomed Pharmacother; 1995; 49(10):465-8. PubMed ID: 8746073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
